What is prophylaxis after exposure for HIV?

prophylaxis after exposure (PEP) for human immunodeficiency virus (HIV), also called HIV-PEP, is a treatment provided to people who are exposed or possibly exposed to HIV to prevent infection. It includes prescription drugs, usually used in a four -week regime, and the patient must be subordinate and tested during treatment to check signs of HIV antibodies after treatment and set interval. People who need prophylaxis after exposure to HIV include an individual exposed to infected blood through the bar needles, bite injuries and certain types of sexual activity. It can be from a needle, an accident during surgery, or as a result of the blood comes into contact with muneting membranes in the eyes, mouth, or nose. The first respondents, such as police or firefighters, can also be exposed to HIV-positive blood in this way.

rape victims can be offered prophylaxis for hIV, as well as other sexually transmitted infections and people can apply for treatment if they have unprotected sexual activity with someone who has HIV or in a situation where transmission could be a risk. The prophylaxis after the HIV exposure includes a mixture of medicines, with a precise cocktail depending on the situation and the protocol followed in the medical facility. Patients must accurately follow the regime, with compliance with critically important. In the case of healthcare professionals, people may have to report to a supervisor or a security officer to get each dose and ensure that they are accepted in order and in time.

At the length of the prophylaxis for HIV, people can experience nausea, vomiting, fever and diarrhea. Medicines can be provided to help people with these side effects if they are serious. Patients may also be recommended to advice if the circumstances of the exposure were traumatic and helped with the stress associated withconcern about HIV infection.

It has been shown that prophylaxis after prophylaxis exposure to reduce the risk of seroconverting, a term used to describe the development of antibodies in the blood, showing that someone is infected with a virus. It is assumed that this advantage will outweigh the risks associated with drug use in most cases. In the case of exposure at the workplace, the employer should pay for drugs and any other necessary treatment.